TY - JOUR
T1 - Surgical management of high risk prostate cancer
T2 - The Mayo Clinic experience
AU - Boorjian, Stephen A.
AU - Blute, Michael L.
PY - 2008/9
Y1 - 2008/9
N2 - Although the prostate specific antigen (PSA) era has altered the clinical and demographic characteristics of men with newly-diagnosed prostate cancer, the impact on patients with high risk disease has been less predictable. We have long advocated aggressive surgical resection for patients with high risk prostate cancer at the Mayo Clinic, including patients with clinical T3 tumors, and have reported our results as well of radical prostatectomy with adjuvant hormonal therapy in the setting of lymph node positive disease. At the same time, multiple predictive models have been developed to assess the risk of disease progression following definitive therapy for prostate cancer. One such model is pretreatment risk group stratification, based on patients' PSA at diagnosis, biopsy Gleason score, and clinical stage. Here, we will review our institution's experience with surgical treatment for men with high risk prostate cancer, and will address the benefits and potential pitfalls of the pretreatment risk group classification model for high risk patients.
AB - Although the prostate specific antigen (PSA) era has altered the clinical and demographic characteristics of men with newly-diagnosed prostate cancer, the impact on patients with high risk disease has been less predictable. We have long advocated aggressive surgical resection for patients with high risk prostate cancer at the Mayo Clinic, including patients with clinical T3 tumors, and have reported our results as well of radical prostatectomy with adjuvant hormonal therapy in the setting of lymph node positive disease. At the same time, multiple predictive models have been developed to assess the risk of disease progression following definitive therapy for prostate cancer. One such model is pretreatment risk group stratification, based on patients' PSA at diagnosis, biopsy Gleason score, and clinical stage. Here, we will review our institution's experience with surgical treatment for men with high risk prostate cancer, and will address the benefits and potential pitfalls of the pretreatment risk group classification model for high risk patients.
KW - Gleason score
KW - Lymph nodes
KW - Prostate cancer
KW - Radical prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=50649115524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50649115524&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2008.03.009
DO - 10.1016/j.urolonc.2008.03.009
M3 - Review article
C2 - 18774468
AN - SCOPUS:50649115524
SN - 1078-1439
VL - 26
SP - 530
EP - 532
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 5
ER -